ArticleOpen forum infectious diseases2023
Seroepidemiology of the Seasonal Human Coronaviruses NL63, 229E, OC43 and HKU1 in France.
Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Temperature-dependent replication and sensitivity to innate immunity of human coronavirus HKU1.Nature communications · 2026Article
- Pandemic-driven immune imprinting accelerates evolution of human coronavirus OC43.PLoS neglected tropical diseases · 2026Article
- Declined Circulation and Seasonal Shifts of Human Coronavirus 229E in the Republic of Korea: Implications for Respiratory Virus Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses.Science translational medicine · 2025Article
- Investigation of the sero-epidemiology of vaccine preventable diseases and common viral infections in French populations.Communications medicine · 2025Article
- Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus.Npj viruses · 2025Article
- Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic.The Journal of infectious diseases · 2025Article
- Article
- Impact of COVID-19 Nonpharmaceutical Interventions onOpen forum infectious diseases · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The seasonal human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 are globally endemic, yet the majority of HCoV infections remain undiagnosed. Methods: In a cross-sectional study, 2389 serum samples were collected from children and adults in France in 2020. In a longitudinal cohort study, 2520 samples were collected from 898 French individuals followed up between 2020 and 2021. Antibodies to HCoVs were measured using a bead-based multiplex assay. Results: The rate of waning of anti-HCoV spike immunoglobulin G antibodies was estimated as 0.22-0.47 year Conclusions: The high force of infection in children indicates that HCoVs may be responsible for a substantial proportion of fever episodes experienced by children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.